Research programme: autoimmune, inflammation and metabolic disease therapeutics - Harbor BioSciences
Alternative Names: HE 3177Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Hollis-Eden Pharmaceuticals
- Developer Harbor Therapeutics
- Class Androstenes; Hormonal steroids; Small molecules
- Mechanism of Action NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation; Metabolic disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Metabolic-disorders in USA (PO)